Breaking News, Collaborations & Alliances

Monopar, Singapore U Collaborate to Evaluate MNPR-101 Radiopharma

To evaluate radiopharmaceutical versions of MNPR-101 in several aggressive cancers.

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company focused on cancer treatments, will collaborate with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) to evaluate radiopharmaceutical versions of MNPR-101 in several aggressive cancers. MNPR-101 is a novel, first-in-class humanized monoclonal antibody to the urokinase Plasminogen Activator Receptor (uPAR). Anand Jeyasekharan, of CSI Singapore, NUS, will be the principal i...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters